In vitro evaluation, biodistribution in rats of radiolabeled raloxifene.
Raloxifene is a selective estrogen receptor modulator that produces both estrogen agonistic effects on bone and lipid metabolism and estrogen-antagonistic effects on uterine endometrium and breast tissue. In the present study, raloxifene was labeled with I-131 by iodogen method and investigated for its radiopharmaceutical potential. Radiolabeling yield is 91+/-0.7%, as determined by radio thin layer chromatography (RTLC). Results of in vitro study indicated (131)I-raloxifene has high stability (4h) in serum. Biodistribution study was carried out with Albino wistar female rats. The result has shown that the radioiodinated raloxifene has higher uptake in uterus than breast and ovarian.
Bayrak
Elif
E
Ege University, Institute of Nuclear Science, Department of Nuclear Applications, Bornova, 35100 Izmir, Turkey.
Lambrecht
Fatma Yurt
FY
Durkan
Kubra
K
Yilmaz
Osman
O
D000818:Animals; D005260:Female; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D020849:Raloxifene Hydrochloride / Q000031:analogs & derivatives* / Q000493:pharmacokinetics*; D051381:Rats; D017208:Rats, Wistar; D020845:Selective Estrogen Receptor Modulators / Q000493:pharmacokinetics*; D014018:Tissue Distribution
D007457:Iodine Radioisotopes; D020845:Selective Estrogen Receptor Modulators; C546836:iodoraloxifene; D020849:Raloxifene Hydrochloride